Currently, a number of miRNAs have been described which may have a specific role in lung cancer pathogenesis, biological and clinical disease behaviour as well as in modulating response to anticancer treatments, particularly EGFR‐TKIs.23, 24, 25, 26 MiR‐345 and miR‐498 were downregulated in NSCLC patients and cell lines, closely correlating with the tumour progression and poor prognosis.16, 17 Our data found that there was a lower expression of miR‐345 and miR‐498 in gefitinib resistant cells than gefitinib sensitive cells. The gene discussed is EGFR; the disease is lung carcinoma.